Puma anticipates $194M-$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs
Source: SeekingAlpha
2026-02-26 21:38:36 ET
More on Puma Biotechnology
- Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript
- Seeking Alpha’s Quant Rating on Puma Biotechnology
- Historical earnings data for Puma Biotechnology
- Financial information for Puma Biotechnology
Read the full article on Seeking Alpha
For further details see:
Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs
Puma Biotechnology Inc
NASDAQ: PBYI
PBYI Trading
1.02% G/L:
$5.96 Last:
77,589 Volume:
$5.88 Open:
PBYI Latest News
February 26, 2026 04:05:00 pm
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
February 23, 2026 04:15:00 pm
Puma Biotechnology to Present at TD Cowen's 46th Annual Health Care Conference
PBYI Stock Data
$345,934,950
38,649,979
14.87%
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Los Angeles
